摘要
目的探讨尤瑞克林对急性脑梗死的临床疗效及安全性。方法将急性发病(6～48 h)的脑梗死患者76例随机分为治疗组42例和对照组34例,分别评价NIHSS评分、ADL评分及NIHSS评分变化情况判定临床疗效,并观察不良反应。结果治疗组的临床疗效明显好于对照组,且无明显不良反应。结论 尤瑞克林治疗急性脑梗死安全有效。
Objective To observe the clinical efficacy and safety of urinary kallikrein on acute cerebral infarction.Methods 76 cases with the acute cerebral infarction within 6-48h were divided into treatment group(n=42) and control group(n=34).Each group was appraised the clinical efficacy by nerve function damage degree(NIHSS),daily life energy(ADL) and the change of the NIHSS and observed the adverse effects.Results The clinical efficacy of the treatment group was much better than that of the control group;moreover,there was no significant adverse effect in two groups.Conclusion It is safe and effective by using urinary kallikrein on acute cerebral infarction.
出处
《临床军医杂志》
CAS
2011年第4期650-652,共3页
Clinical Journal of Medical Officers
关键词
尤瑞克林
急性脑梗死
临床疗效
urinary kallikrein
acute cerebral infarction
clinical efficacy
